AbbVie's immunology franchise is firing on all cylinders while Bristol Myers Squibb navigates revenue declines and legal ...

AbbVie is profitable, growing, and paying a rising dividend. CRISPR is burning cash in pursuit of a gene-editing breakthrough ...

AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...

AbbVie's dividend is a very appealing factor.

Pfizer's 6% dividend yield is enticing, but AbbVie's dividend growth is superior.

AbbVie Inc. (ABBV), the North Chicago, Illinois-based Pharma giant, is expected to report its Q1 2026 earnings around April 29th - in just under three weeks' time. A few days ago, AbbVie released an 8 ...

AbbVie remains a buy, as recent EPS guidance reductions are driven by normal IPR&D and milestone expenses, not operational weakness. Their Q4 showed robust 10% revenue growth and a 38.3% adjusted ...

AbbVie stock closed at USD 261.77 on the NYSE on September 14, 2026, marking a 1.81 percent gain versus its prior close and ...

Now, it’s worth noting Stock Advisor’s total average return is 895 % — a market-crushing outperformance compared to 206% for ...

Tue, June 16, 2026 at 5:30 PM UTC AbbVie (NYSE:ABBV) has quietly become one of healthcare's most underrated growth stories. CEO Robert A. Michael told investors after Q1, "We are off to an excellent ...

Detailed price information for Apogee Therapeutics Inc (APGE-Q) from The Globe and Mail including charting and trades.

AbbVie's flagship drug is bleeding revenue quarter after quarter, yet the company just handed shareholders another raise. Find out whether the cash machine holding this payout together can survive the ...